Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Remibrutinib · Rhapsido, LOU064

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Novartis

Approved FDA, Sep 2025
NVS Developer
1 Registered trials

What is Remibrutinib?

Remibrutinib is an oral small-molecule kinase inhibitor that blocks Bruton's tyrosine kinase (BTK), along with the related kinases TEC and BMX. It inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators driven by pathogenic IgE or IgG.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rhapsido, LOU064, LOU064-NXA
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC) (secondary target), BMX non-receptor tyrosine kinase (BMX) (secondary target)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
FcεR1 signaling, FcγR signaling, B cell antigen receptor signaling, mast cell and basophil degranulation
Therapy area
Dermatology
Developer
Novartis (NVS)
FDA status
Approved as Rhapsido (September 30, 2025), NDA218436 · FDA label
UNII
I7MVZ8HDNU

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05156281 Phase 3 Relapsing Multiple Sclerosis Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Papulopustular RosaceaRelapsing Multiple Sclerosis

Other drugs acting on BTK

More from Novartis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Remibrutinib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.